Kornimate/medical-research-clean huggingface dataset:
improve the strategies of endoscopic and interventional treatment of gastroesophageal hemorrhage in portal hypertension

Conditions: Esophageal Varices; Portal Hypertension

Summary: endoscopic esophageal variceal ligation combined with gastric variceal embolization using tissue glue is currently the first-choice method for preventing rebleeding in patients with cirrhosis and portal hypertension. however, the rebleeding rate remains relatively high. factors such as extra-luminal vascular bundles in the esophagus and stomach walls, and portosystemic shunts significantly affect the therapeutic outcomes. therefore, there is an urgent need to develop an individualized treatment model for esophagogastric varices based on the anatomical and hemodynamic characteristics of the varices, to stratify patient risks and provide tailored treatment options. before the treatment of esophagogastric varices, the vascular characteristics of esophagogastric varices are assessed based on imaging data such as portal venous ct and ultrasound, as well as clinical information. risk factors influencing bleeding from esophagogastric varices are explored, and an endoscopic and interventional variceal stratification and treatment model is constructed to provide patients with personalized options for endoscopic or interventional therapy. during the treatment of esophagogastric varices, precise endovascular embolization of the source branch vessels of esophagogastric varices is performed based on hemodynamic models. the safety and efficacy of this treatment strategy are verified through randomized controlled clinical trials. after the treatment of esophagogastric varices, the feasibility of reducing the risk of rebleeding in patients with poor endoscopic outcomes is examined by using drugs that lower portal venous pressure, such as carvedilol or novel oral anticoagulants. factors influencing recompensation and reversal of portal hypertension are also clarified.


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of portal hypertension; 2. underwent imaging and endoscopic examination or treatment within one week after admission; 3. endoscopy revealed the presence of esophageal and/or gastric varices. exclusion criteria: 1. ct image slice thickness does not meet the requirements or there are artifacts; 2. endoscopy shows no presence of esophageal and/or gastric varices; 3. presence of severe life-threatening diseases of the circulatory, hematological, or respiratory systems; 4. lack of important historical medical information or other relevant data.

Keywords: endoscopic treatment
evaluation of the simplified treat and extend regimen using ranibizumab in exudative age related macular degeneration

Conditions: Exudative Age-related Macular Degeneration

Summary: recently studies have shown that intravitreal injection of ranibizumab is effective for age related macular degeneration. however there are problems about injection regimen of maintenance phase. we plan to perform new simplified treat and extend regimen using ranibizumab.

the purpose of the present study is to evaluate the simplified treat and extend regimen using ranibizumab in eyes with wet age related macular degeneration about best-corrected visual acuity, central retinal thickness, the disappearance rate of the morphological change and treatment continuous rate.

Eligibility criteria:
inclusion criteria: 1. ability to provide written informed consent for this study 2. age\>=50years old 3. intravitreal injection of ranibizumab as a first therapy for neovascular age-related macular degeneration (typical age-related macular degeneration and pcv) 4. best corrected visual acuity\>=0.05 - exclusion criteria: 1. past intravitreal anti-vascular endothelial growth factor therapy in the study eye 2. past intravitreal or subtenon injection of steroid therapy in the study eye 3. past vitrectomy therapy in the study eye 4. infection or suspicion of infection in eyes or periocular region 5. severe intraocular inflammation in eyes 6. past allergic reaction for ranibizumab 7. past allergic reaction for fluorescein, indocyanine green or iodine 8. pregnancy (positive pregnancy test) or lactating women 9. other conditions that the investigator believed would pose a significant hazard to the subject if investigational therapy were initiated.
promoting inclusive educational environments for children with autism and other social-communication challenges: preschool class and primary school

Conditions: Autism Spectrum Disorder; Social Communication Challenges

Summary: this study evaluates the effect of using the autism program environment rating scale (apers) as the foundation for providing feedback, in-service training and coaching to teachers, to improve program quality for autistic (asd) students and students with related social-communication challenges (scc) in swedish primary school classrooms. in the current study half of the participating classrooms will receive the apers-based model for program quality improvement, while the other half will receive services as usual. it is hypothesized that the apers-based model will improve primary school program quality for children with asd and scc, as well as improve functioning for students with asd/scc and self-perceived self-efficacy among participating teachers, compared to the study's comparison group.


Eligibility criteria:
inclusion criteria: * autism diagnosis * socio-communicative challenges identified by parents and/or school staff * attending a primary school classroom (i.e., from pre-school class to third grade)
effect of neuro developmental therapy in infants with down syndrome

Conditions: Down Syndrome

Summary: neurodevelopmental treatments are a progressive therapeutic method experienced thru qualified therapists for the improvement in affected ones. the most important trial in down syndrome children is motor milestones and postural reactions to develop on time. neurodevelopmental therapy is applied to accurate atypical postural tone and to enable further regular motion for execution of presentation of abilities. objective: to determine the effects of neuro developmental therapy in improving postural reaction and motor milestones in infants with down syndrome.

this study was a randomized trial design. this study was conducted in rehab care physiotherapy department. 20 children with down syndrome meeting the predetermined inclusive and exclusive criteria were arbitrarily allocated into dual batches through convenient sampling technique. the first batch which was the experimental group was given neurodevelopmental therapy and the duration of the treatment comprised of 1.5 hour, three days a week for 6 weeks. the second group which was the control group received conventional therapy and the period of the ministrations comprised of 1 hour, with 10 repetition 3 sets for each muscle three days a week for 1.5 months, pre-assessment and post-assessment was evaluated through gross motor function-88. recorded values were analyzed through spss.

Eligibility criteria:
inclusion criteria: * trisomy 21 by genetic karyotype. * down syndrome children with delayed milestone. * definite identification of down syndrome by neurologist. * children having the average birth weight above 2.500 grams and average birth length above 49.52 cm. * laxity, low muscle tone and psychomotor development deficits exclusion criteria: * infants with heart defect. * seizure. * critical orthopedic difficulties or deformities (hip instability, patellar instability, foot deformity). * unrestrained thyroid conflicts. * perilabour asphyxia (apgar of minutes 1 and 5 equal to or less than 7). * critical optical or acoustic disorders. * mass below the 3rd percentage of down syndrome

Keywords: down syndrome children gross motor function neurodevelopmental treatment rehabilitation milestones postural reactions
effect of time delay and syringe surface area on blood gas samples analysis

Conditions: Respiratory Failure

Summary: to detect the effect of time delay and syringe surface area on the oxygen tension (pao2), oxyhaemoglobin saturation (sao2), acidity (ph), and carbon dioxide tension (paco2) in both arterial and venous blood gas outcomes.

arterial blood gas (abg) analysis and monitoring is a crucial process for the diagnosis and management of the oxygenation status and acid-base balance of high-risk patients during surgery, as well as for the critical care of critically ill patients in the intensive care unit . acid-base imbalance anomalies can have major repercussions in a number of medical scenarios, and in a few rare instances, they may even be a risk factor for death. abg test explores the arterial blood's ph, oxyhaemoglobin saturation (sao2), bicarbonate concentration (hco3), oxygen tension (pao2), and carbon dioxide tension (paco2). traditionally, the concept "blood gas testing" has been used to describe measuring the blood's ph, oxygen saturation of haemoglobin (sao2), and partial pressures of the physiologically active gases (po2, pco2). but now available commercial equipment can measure electrolytes (sodium, potassium, chloride, ionized calcium, and magnesium), glucose, lactate, and creatinine, usually all at the same time, in addition to haemoglobin quantification and co-oximetry

Eligibility criteria:
inclusion criteria: * critically ill-patients, and intraoperative patients who aged above 18 years. exclusion criteria: * patients with haematological diseases e.g. sickle cell anaemia * burn patients with risk of carbon monoxide poisoning * ards * pulmonary oedema * samples that were clotted

Keywords: blood gas oxygen saturation syringe surface area time delay
a study in men with overweight to test how well different doses of bi 1820237 are tolerated when given as an injection alone or in combination with liraglutide

Conditions: Healthy

Summary: the main objective of this trial is to investigate safety, tolerability and pharmacokinetics (pk) and pharmacodynamics (pd) of bi 1820237 alone or together with a single low dose of liraglutide in male subjects with overweight/obesity (otherwise healthy) following subcutaneous administration of single rising doses.


Eligibility criteria:
inclusion criteria: * male subjects with overweight/obesity (otherwise healthy) according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (bp), pulse rate (pr)), 12 lead electrocardiogram (ecg), and clinical laboratory tests * age of 18 to 50 years (inclusive) * body mass index (bmi) of 25.0 to 34.9 kg/m2 (inclusive). overweight should be due to excess adipose tissue, as judged by the investigator * body weight greater than or equal to 70 kg * signed and dated written informed consent prior to admission to the study, in accordance with good clinical practice (gcp) and local legislation exclusion criteria: * any finding in the medical examination (including bp, pr or ecg) deviating from normal and assessed as clinically relevant by the investigator * repeated measurement of systolic blood pressure outside the range of 90 to 140 millimeter of mercury (mmhg), diastolic blood pressure outside the range of 50 to 90 mmhg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) * any laboratory value outside the reference range that the investigator considers to be of clinical relevance * any evidence of a concomitant disease assessed as clinically relevant by the investigator * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medications except appendectomy or simple hernia repair * diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders * history of relevant orthostatic hypotension, fainting spells, or blackouts further exclusion criteria apply
strata: safe testing of risk for asymptomatic microhematuria

Conditions: Hematuria; Urothelial Carcinoma

Summary: to evaluate the clinical utility associated with the integration of cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (uc) without compromising detection of uc.

randomised two arm pragmatic clinical study to be conducted at multiple sites in us and canada. the trial will recruit hematuria subjects, presenting to qualified sites (academic, community), who are being evaluated for urothelial carcinoma (uc). up to 100 consecutive eligible subjects will be recruited per site.

Eligibility criteria:
inclusion criteria: * patient is undergoing investigation of recent confirmed hematuria, as defined by the aua/sufu guideline (barocas da, boorjian sa, alvarez rd et al. microhematuria: aua/sufu guideline, j urol 2020; 204:778) (by either flexible or rigid cystoscopy/turbt), including hematuria subjects referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma. * able to provide a voided urine sample of the required minimum volume * able to give written consent * able and willing to comply with study requirements * aged 18 years or older exclusion criteria * prior history of bladder malignancy or pelvic radiotherapy. prior history prostate or renal cell carcinoma within the last 5 years. * prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection, * known current pregnancy
efficacy of laflavon in lowering triglycerides and raising high-density lipoprotein (hdl)

Conditions: Metabolic Disease

Summary: a trial of laflavon in patients with metabolic syndrome to evaluate its effectiveness in lowering triglycerides and raising high-density lipoprotein (hdl).


Eligibility criteria:
inclusion criteria: 1. men and women with metabolic syndrome 2. elevated triglycerides (\> 150) 3. low high-density lipoprotein (hdl) (\< 35) 4. willingness to take study nutritional supplement once a day for 3 months exclusion criteria: 1. women who are pregnant, nursing, or who intend pregnancy during the period of treatment 2. known milk, soy or whey allergy

Keywords: metabolic
bacteria endotoxin in peritoneal dialysis effluent as a predictor of relapsing, recurrent, and repeat peritonitis

Conditions: Peritoneal Dialysis Associated Peritonitis

Summary: peritoneal dialysis (pd) is the first-line treatment of end stage renal disease (esrd) in hong kong. despite the advances in antibiotic therapy and connecting system, recurrent peritonitis remains the major cause of peritoneal failure. a reliable predictor of relapsing peritonitis is invaluable in the management of pd peritonitis. recent studies showed that bacterial-derived lipopolysaccharide (lps) fragments are present in clinically used fluids such as dialysis fluid. lps are thought to be derived from microorganisms inhabiting body fluid. the investigators hypothesize that the presence of lps in pd effluent is a predictor of relapsing peritonitis in pd patients. the investigators plan to study 300 patients with pd peritonitis. after inform consent, specimens of pd effluent will be collected on the day of initiating antibiotic treatment, every 5 days until the day of completing antibiotic treatment, and then 28 days later for the test of lps level. all patients will be followed for one year after completion of antibiotic therapy for the development of relapsing, recurrent, or repeat peritonitis episodes. our study would explore the use of detecting lps in pd effluent as a non-invasive tests for the prediction of relapsing peritonitis.


Eligibility criteria:
inclusion criteria: at least two of the followings: 1. abdominal pain or cloudy pd effluent; 2. leukocytosis in pd effluent (wbc \> 100/ml); and 3. positive gram-stain or culture from pd effluent exclusion criteria: * mycobacterial peritonitis * obvious surgical problems and require laparotomy

Keywords: renal failure survival peritoneal failure
treatment of adult growth hormone deficiency after traumatic brain injury

Conditions: Brain Injuries; Growth Hormone Deficiency

Summary: to establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.

the study was terminated on 15-dec-2008 due to an inability to recruit the protocol specified patient population. the study has not been terminated due to any safety concerns.

Eligibility criteria:
inclusion criteria: * have had a previous traumatic brain injury (more than 1 year and less than 20 years) prior to the screening visit. * have an extended glasgow outcome scale (gos-e) more than or equal to 5. * have proven ghd deficiency exclusion criteria: * active systemic malignancy or active intracranial tumor. a successfully treated tumor or malignancy is not an exclusion criterion if the patient has not had active disease for 5 years and is not currently receiving maintenance chemotherapy, (except for basal cell skin cancers. * receiving treatment with prednisolone in doses above 10 mg/day or treatment with other oral glucocorticosteroids above replacement doses is not permitted throughout the study. topical and inhaled corticosteroids are permitted. * history of dementia unrelated to tbi * history of benign intracranial hypertension

Keywords: traumatic brain injury, cognitive function
prevalence of il28b polymorphism in hepatitis c patients

Conditions: Hepatitis C

Summary: response to peginterferon and ribavirin treatment in hepatitis c (hcv) depends on viral and host factors. single nucleotide polypmorphisms (snp) near to il28b gene (especially at rs12979860 and rs8099917) are strongly associated with the response to treatment in hcv genotype 1 infection, less so in hcv genotype 2/3 infection. cc genotype in rs12979860 and tt genotype at rs8099917 are associated with good treatment outcome. asian populations have high prevalence of cc genotype in other studies, which can explain relatively good response to peginterferon/ ribavirin in genotype 1 infection in asians compared with caucasians.

the prevalence of different genotypes of il28b polymorphism in the local population will be studied. dna will be extracted from the whole blood sample of hepatitis c patients with genotype 1, 2 and 3 infection. it will be amplified by real-time pcr and subsequently analysed for the genotypes of il28b snps.

Eligibility criteria:
inclusion criteria: * patients with positive hcv igg (eia or riba test) and positive hcv rna test (rt-pcr) * hcv genotypes 1, 2 or 3 (determined by versant™ hcv genotype assay lipa 2.0) * with or without hcv treatment (peginterferon/ ribavirin). exclusion criteria: -patients with acute hepatitis c infection.

Keywords: il28b gene
nasal ointment on epistaxis of nasotracheal intubation in children

Conditions: Epistaxis; Intubation

Summary: nasotracheal intubation is one of the anesthetic procedures required for oral surgery. it allows the surgeon easier access to the surgical site than the orthotracheal intubation. therefore, nosotracheal intubation is commonly used for general anesthesia for oral and maxillofacial surgery and dental treatment. however, nasotracheal intubation can damage the nasal mucosa in the course of the tube passing through the nostrils, causing epistaxis which is reported as the most common side effect. in order to reduce these side effects, heating of the tube and use of a tube lubricant immediately before intubation have been recommended in children. however, research on whether the dry state of the mucosa itself contributes to the development of epistaxis is limited. a study in adults reported that pretreatment of the ointment on the mucosa reduced the damage to the mucosa. however, its effect on the incidence of epistaxis in children has not been studied. the purpose of this study is to investigate the effects of pretreatment of nasal ointment on epistaxis of nasotracheal intubation in children.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical statue i or ii * patients scheduled to undergo surgery under nasotracheal intubation exclusion criteria: * expected difficult intubation based on history, physical examination, weight. * bleeding tendency * upper respiratory infection within the previous 14 days
interferon lambda therapy for covid-19

Conditions: SARS-CoV-2

Summary: the main purpose of this research study is to test the safety and effectiveness of an investigational drug peginterferon lambda-1a in treating covid-19.

primary objective: determine efficacy of pegylated interferon lambda as measured by clinical improvement. this will be defined as improvement in supplemental oxygen requirement. secondary objectives: * determine safety and tolerability of pegylated interferon lambda * days with fever * time to resolution of fever * rate of progression to requiring critical care * overall survival * time to discharge exploratory objectives: determining the effect systemically on inflammatory markers in the blood, as well as viral load. diagnosis and main inclusion criteria: patients must have a confirmed diagnosis of infection with sars-cov-2 and be receiving supplemental oxygen. many patients may be receiving hydroxychloroquine with or without other antimicrobials.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of sars-cov-2 * hospitalization due to diagnosis with sars-cov-2 * sp02 \< 93% on ambient air or pao2/fio2 \< 300 mmhg and requires supplemental oxygen exclusion criteria: * patients must not be pregnant or nursing * patients cannot be admitted to intensive care unit at time of admission or require positive pressure ventilation * patients cannot be requiring continuous supplemental oxygen normally (pre-sars-cov-2) * patient is receiving steroids \>1mg/kg * has diagnosis of primary immunodeficiency * has active autoimmune disease that has required systemic treatment in the past year * has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial * patients with ferritin \>2000ng/ml and/or c-reactive protein \>100mg/l * history of allogeneic hematopoietic cell transplantation or solid organ transplantation * childs-pugh class b or c cirrhosis or class a if portal hypertension is present * documented allergic or hypersensitivity response to protein therapeutics * no serious disease requiring mechanical ventilation at time of enrollment

Keywords: peginterferon lambda-1a lambda sars-cov-2